Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Cash & Equivalents (2016 - 2025)

Neuronetics (STIM) has disclosed Cash & Equivalents for 10 consecutive years, with $28.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 34.04% to $28.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $28.0 million, a 34.04% increase, with the full-year FY2024 number at $1.0 million, down 98.32% from a year prior.
  • Cash & Equivalents was $28.0 million for Q3 2025 at Neuronetics, up from $11.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $121.3 million in Q1 2021 to a low of $1.0 million in Q4 2024.
  • A 5-year average of $57.6 million and a median of $55.4 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 114.44% in 2021, then tumbled 98.32% in 2024.
  • Neuronetics' Cash & Equivalents stood at $94.1 million in 2021, then decreased by 25.28% to $70.3 million in 2022, then dropped by 15.16% to $59.7 million in 2023, then crashed by 98.32% to $1.0 million in 2024, then surged by 2697.1% to $28.0 million in 2025.
  • Per Business Quant, the three most recent readings for STIM's Cash & Equivalents are $28.0 million (Q3 2025), $11.0 million (Q2 2025), and $20.2 million (Q1 2025).